Reboul P, George P, Louisot P, Broquet P
Laboratoire de Biochimie Générale et Médicale, INSERM-CNRS U.189 Faculté de Médecine Lyon-Sud, Oullins, France.
Biochem Mol Biol Int. 1995 Aug;36(5):1097-105.
Using monoclonal antibodies against the RAR-alpha and RAR-beta retinoic receptors, we demonstrated that these receptors were present together in C6 glioma cells as two isoforms of 50 and 55 kDa. For RAR-beta, the 50 kDa isoform predominated (60 to 80% of the total of the two isoforms). After a treatment for 48 h with retinoic acid 10 microM, the 55 kDa form was enhanced, while no effect was observed either on RAR-alpha isoforms from C6 cells and on both RAR-alpha and RAR-beta forms from neuroblastoma SKN SH SY5Y used as a control. Using purified neuronal and glial rat brain nuclei, we showed that the 55 kDa isoform from RAR-beta predominated in glial cells. These results suggest that retinoic acid treatment of C6 cells led to a partial differentiation, the enhancement of the heavy form of RAR-beta being a marker of this phenomenon.
利用针对视黄酸受体RAR-α和RAR-β的单克隆抗体,我们证明这些受体以50 kDa和55 kDa两种亚型的形式共同存在于C6胶质瘤细胞中。对于RAR-β,50 kDa亚型占主导地位(占两种亚型总量的60%至80%)。用10 microM视黄酸处理48小时后,55 kDa形式增加,而对C6细胞的RAR-α亚型以及用作对照的神经母细胞瘤SKN SH SY5Y的RAR-α和RAR-β形式均未观察到影响。使用纯化的大鼠脑神经元和神经胶质细胞核,我们发现RAR-β的55 kDa亚型在神经胶质细胞中占主导地位。这些结果表明,视黄酸处理C6细胞导致部分分化,RAR-β重形式的增加是这一现象的标志。